260 Results for "

trial

" in MedChemExpress (MCE) Product Catalog:
Products (260)

260 Results for "trial" in MCE Product Catalog:

23
23 Publications Verification
Cat. No.: HY-16997A
CAS No.: 1334302-63-4
Target:  

JAK

Research Areas:  

Cancer

Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.
3
3 Cited Publications
Cat. No.: HY-15615
CAS No.: 41276-02-2
Purity:  99.91%
Synonyms: ONC201 isomer
Target:  

Others

Research Areas:  

Others

TIC10 isomer is the isomer of TIC10. TIC10 isomer does not possess the reported biological activity of inducing TRIAL expression.
3
3 Cited Publications
Cat. No.: HY-75958
CAS No.: 511-28-4
Synonyms: 22-Dihydroergocalciferol
Target:  

VD/VDR

Research Areas:  

Metabolic Disease

Vitamin D4 (22-Dihydroergocalciferol) is a Vitamin D derived from fungi. The precursor of Vitamin D4 is 22,23-dihydroergosterol .
Cat. No.: HY-P991628
Synonyms: PF-08634404

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .
Cat. No.: HY-P99845
CAS No.: 2245953-10-8
Synonyms: MEDI 4920; VIB 4920

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Dazodalibep (MEDI 4920; VIB 4920) is a non-antibody fusion protein that targets CD40L. Dazodalibep inhibits the co-stimulatory signals between immune cells (such as T cells, B cells, and antigen-presenting cells), thereby enabling the inhibition of a broader range of cellular and humoral responses. Dazodalibep can be used for research on rheumatoid arthritis and Sjögren's syndrome .
Cat. No.: HY-100074
CAS No.: 1988-11-0
Target:  

Drug Intermediate

Research Areas:  

Others

2,6-Diisopropyl-p-benzoquinone is a drug intermediate that can be used for the synthesis of Geldanamycin (HY-15230) .
Cat. No.: HY-P991492

Target:  

RSV

Research Areas:  

Infection

RSM-01 is a monoclonal antibody targeting site Ø of the pre-fusion F glycoprotein (Fusion glycoprotein F0) of respiratory syncytial virus (RSV). RSM-01 can be used in studies related to RSV infection .
Cat. No.: HY-119220
CAS No.: 594842-13-4
Synonyms: JTT-130
Granotapide is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces the absorption of cholesterol and triglycerides by inhibiting MTP. Granotapide can be used in the research of coronary artery disease, obesity, diabetes mellitus and hypertension .
Cat. No.: HY-16632
CAS No.: 1333990-84-3
Target:  

γ-secretase Amyloid-β

Research Areas:  

Metabolic Disease

ELND 006 (Compound 30) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Aβ levels in vitro and in vivo. Comparisons with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Aβ levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimer's disease .
Cat. No.: HY-P3388
CAS No.: 2460862-12-6
Target:  

GLP Receptor

Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity .
Cat. No.: HY-116229
CAS No.: 175463-14-6
Synonyms: SB-265805; LB20304
Target:  

Antibiotic Bacterial

Research Areas:  

Infection

Gemifloxacin, a fluoroquinolone, is a potent and orally active antipneumococcal agent. Gemifloxacin shows bactericidal activity against highly quinolone-resistant pneumococci.Gemifloxacin can be used for the research of respiratory infections, such as community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB) .
Cat. No.: HY-W017428
CAS No.: 10031-82-0
Synonyms: P-Ethyoxybenzaldehyde
4-Ethoxybenzaldehyde (P-Ethyoxybenzaldehyde) is a derivative of benzaldehyde. 4-Ethoxybenzaldehyde can significantly inhibit the production of key inflammatory factors such as prostaglandin E2 (PGE2), IL-6, and IL-8 induced by ultraviolet radiation (UVR). 4-Ethoxybenzaldehyde shows significant efficacy and good safety in reducing facial redness when added to an oil-in-water emulsion at a concentration of 1%. 4-Ethoxybenzaldehyde can be used in the study of chronic inflammatory skin diseases .
Cat. No.: HY-107121
CAS No.: 676501-25-0
Synonyms: LY 2196044
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Ondelopran (LY 2196044) is a non-selective opioid receptor antagonist. Ondelopran inhibits the release of dopamine in the nucleus accumbens induced by alcohol, reduces the rewarding effect of alcohol consumption, and lowers the craving. Ondelopran can be used for alcohol use disorder (AUD) .
Cat. No.: HY-14955A
CAS No.: 347870-26-2
Synonyms: (Rac)-MB06322; (Rac)-CS-917
Target:  

Others

Research Areas:  

Others

(Rac)-Managlinat dialanetil ((Rac)-MB06322) is a compound for the inhibition of type 2 diabetes that is in Phase II clinical trials and works by inhibiting gluconeogenesis.
Cat. No.: HY-19500
CAS No.: 215122-74-0
Target:  

COX

Research Areas:  

Others

SC-75416 is a selective cyclooxygenase-2 inhibitor. Its pharmacokinetic/pharmacodynamic (PK/PD) model was used for development and clinical trial simulation to design a study protocol to verify its analgesic effect in a post-oral surgery pain model. The simulation results showed that 360 mg of SC-75416 may provide better pain relief than 400 mg of ibuprofen. The actual clinical trial results confirmed this hypothesis, and 360 mg of SC-75416 was indeed superior to 400 mg of ibuprofen in pain relief. The PK/PD model of SC-75416 showed good predictive performance and successfully predicted its clinical effect. These research results show that SC-75416, as a new selective COX-2 inhibitor, has potential clinical application value in the management of post-oral surgery pain.
Cat. No.: HY-125856A
CAS No.: 1802426-00-1
Synonyms: BMS-986177 TFA; JNJ-70033093 TFA
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
Cat. No.: HY-106981
CAS No.: 137109-78-5
Synonyms: OR 1384
Orazipone (OR 1384) is a small molecule immunomodulator with strong anti-inflammatory properties. Orazipone exerts its immunomodulatory effect by forming reversible thiol complexes, which bind to intracellular signaling proteins and the thiol groups of glutathione. Orazipone exhibits potent anti-eosinophilic activity by inducing apoptosis. Orazipone inhibits activation of inflammatory transcription factors NF-kB and STAT 1 and decreases inducible iNOS expression and NO production in response to inflammatory stimuli. Orazipone reduces NADPH oxidase activity and thereby decreases ROS production. Orazipone has a protective effect in intestinal radiation injury .
Cat. No.: HY-119916
CAS No.: 85977-49-7
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Tauromustine is an orally active nitrosourea anticancer agent. Tauromustine has an alkylation effect and can damage the DNA function. Tauromustine has a high therapeutic index, especially in the study of Walker 256 rat sarcoma. It is also active against melanoma, breast cancer, pleural mesothelioma and ovarian cancer. Tauromustine is mainly metabolized in the liver, but some of its metabolites also have cytotoxicity .
Cat. No.: HY-177878
CAS No.: 2303528-97-2
Target:  

Sirtuin

Research Areas:  

Inflammation/Immunology

IMU-856 is an orally active and systemic action SIRT6 small molecule regulator. IMU-856 effectively and selectively inhibits the deacetylase activity of SIRT6, while increasing the protein level of SIRT6. IMU-856 can restore intestinal barrier function and can be used for research on celiac disease .
Cat. No.: HY-14977
CAS No.: 840523-39-9
Target:  

LPL Receptor

Research Areas:  

Inflammation/Immunology

CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS) .